Price Alert

Tonix Pharmaceuticals Hol... (TNXP)

NASDAQ: TNXP · Real-Time Price · USD

37.82

-2.25 (-5.62%)

At close: Aug 19, 2025, 10:24 AM

-5.62% (1D)

Bid	37.65
Market Cap	331.56M
Revenue (ttm)	10.04M
Net Income (ttm)	-115.1M
EPS (ttm)	2537
PE Ratio (ttm)	0.01
Forward PE	-7.64
Analyst	Buy

Ask	37.81
Volume	1,840,391
Avg. Volume (20D)	1,427,846
Open	36.90
Previous Close	40.07
Day's Range	34.00 - 38.83
52-Week Range	6.76 - 130.00
Beta	1.72

About TNXP

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TNXP

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TNXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Tonix Pharmaceuticals has released their quartely earnings on Aug 11, 2025:

Revenue of $2M misses estimates by $422K, with -9.51% YoY decline.

EPS of -3.86 misses estimates by -1.49, with 99.80% YoY growth.

Next Earnings Release

Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

+32.89%

Tonix Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

1 month ago

+10.43%

Tonix Pharmaceuticals shares are trading higher after the company announced the presentation of new findings on TNX-801 at the Vaccine Congress 2025 in Vienna.

News

19 hours ago · investors.com

FDA Approves New Fibromyalgia Drug, Tonix Shares Climb

Tonmya is the first FDA-approved fibromyalgia drug in more than 15 years.

2 days ago · seekingalpha.com

Tonix Secures Fibromyalgia Approval - What Investors Should Know

Tonix's Tonmya received FDA approval, marking the first new fibromyalgia therapy in 15 years and driving a post-market stock surge. Despite the approval, I maintain a Hold rating due to Tonix's limite...

4 days ago · reuters.com

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

The U.S. Food and Drug Administration has approved Tonix Pharmaceuticals' drug to manage pain related to a type of chronic condition, the company said on Friday.

2 months ago · seekingalpha.com

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved mar...

2 months ago · seekingalpha.com

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Tonix Pharmaceuticals' TNX-102 SL shows a high probability of FDA approval for fibromyalgia, supported by positive Phase 3 trials and an acceptable safety profile. A recent $500M shelf offering caused...